These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3134315)

  • 21. Platelet alloimmunization after transfusion. A prospective study in 117 heart surgery patients.
    Taaning E; Simonsen AC; Hjelms E; Svejgaard A; Morling N
    Vox Sang; 1997; 72(4):238-41. PubMed ID: 9228715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness.
    Seftel MD; Growe GH; Petraszko T; Benny WB; Le A; Lee CY; Spinelli JJ; Sutherland HJ; Tsang P; Hogge DE
    Blood; 2004 Jan; 103(1):333-9. PubMed ID: 12958065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ultraviolet light-based pathogen inactivation and alloimmunization after platelet transfusion: results from a randomized trial.
    Norris PJ; Kaidarova Z; Maiorana E; Milani S; Lebedeva M; Busch MP; Custer B; Rebulla P
    Transfusion; 2018 May; 58(5):1210-1217. PubMed ID: 29473173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention and circumvention of refractoriness to platelet transfusions: interface between preparative and therapeutic apheresis.
    Beris P; Dornier C
    Curr Stud Hematol Blood Transfus; 1990; (57):267-76. PubMed ID: 2272206
    [No Abstract]   [Full Text] [Related]  

  • 25. Platelet transfusions a constantly evolving therapy.
    Slichter SJ
    Thromb Haemost; 1991 Jul; 66(1):178-88. PubMed ID: 1926048
    [No Abstract]   [Full Text] [Related]  

  • 26. Dynamism of the development of "Fc receptor-blocking antibodies" after immunization with buffy coat.
    Petri IB; Gyódi E; Kaiser G; Kassai M; Petrányi GG
    Haematologia (Budap); 1989; 22(3):135-41. PubMed ID: 2684813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of HLA alloimmunization: role of leukocyte depletion and UV-B irradiation.
    Snyder EL
    Yale J Biol Med; 1990; 63(5):419-27. PubMed ID: 2293501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Marginal zone B cells are responsible for the production of alloantibodies following platelet transfusion in mice.
    Couvidou A; Angénieux C; Ruch L; Mangin PH; Gachet C; Maître B
    Blood Adv; 2023 Apr; 7(8):1356-1365. PubMed ID: 36490266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vincristine therapy for severe platelet alloimmunization.
    Bruggers CS; Kurtzberg J; Friedman HS
    Am J Pediatr Hematol Oncol; 1991; 13(3):300-4. PubMed ID: 1793156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Canine platelet alloimmunization: the role of donor selection.
    Slichter SJ; O'Donnell MR; Weiden PL; Storb R; Schroeder ML
    Br J Haematol; 1986 Aug; 63(4):713-27. PubMed ID: 3730294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Immunological support of component blood transfusion therapy].
    Shablin VN; Serova LD; Abdulkadyrov KM; Mel'nikova VN
    Probl Gematol Pereliv Krovi; 1978 Aug; 23(8):3-7. PubMed ID: 683985
    [No Abstract]   [Full Text] [Related]  

  • 32. Alloimmunization after granulocyte transfusions.
    Stroncek DF; Leonard K; Eiber G; Malech HL; Gallin JI; Leitman SF
    Transfusion; 1996; 36(11-12):1009-15. PubMed ID: 8937413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sensitization by platelet transfusion.
    Brand A
    Schweiz Med Wochenschr; 1991 Mar; 121(13):467-9. PubMed ID: 2031162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stability of antigens on leukocytes in banked platelet concentrates: decline in HLA-DR antigen expression and mixed lymphocyte culture stimulating capacity following storage.
    Sherman ME; Dzik WH
    Blood; 1988 Sep; 72(3):867-72. PubMed ID: 2970874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Platelet transfusion refractoriness and effective management of platelet alloimmunization].
    Amemiya Y
    Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.
    Trial to Reduce Alloimmunization to Platelets Study Group
    N Engl J Med; 1997 Dec; 337(26):1861-9. PubMed ID: 9417523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FcR blocking activity in serum of actively enhanced rat renal allograft recipients due to IgG anti-class II MHC alloantibody.
    Marshall HE; Bolton EM; Gracie JA; Cocker JE; Sandilands GP; Bradley JA
    Immunology; 1990 Mar; 69(3):379-84. PubMed ID: 2312162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship of HLA and platelet-reactive antibodies in alloimmunized patients refractory to platelet therapy.
    Brubaker DB; Romine M
    Am J Hematol; 1987 Dec; 26(4):341-52. PubMed ID: 3687931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biologic effects of leukocytes present in transfused cellular blood products.
    Bordin JO; Heddle NM; Blajchman MA
    Blood; 1994 Sep; 84(6):1703-21. PubMed ID: 8080981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of leukocyte depletion and UVB irradiation on alloantigenicity of major histocompatibility complex antigens in platelet concentrates: a comparative study.
    Kao KJ
    Blood; 1992 Dec; 80(11):2931-7. PubMed ID: 1450418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.